🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial 🎙️ @charlesrudin 🔢3808O …

HHorinouchi· @HHorinouchi · X·2026-10-21 20:30· 2 days agoScore60

Body · original

🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial 🎙️ @charlesrudin 🔢3808O 🎯Durable OS Benefit at 23-Mo Median Follow-Up 🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24% 🎯Grade≥3 TRAEs 28% vs 63% ☑️NCT05740566 🔗 https://t.co/grEfaUbJVf @OncoAlert @Larvol @myESMO @IASLC

Heat 5 · 4 likes · 0 replies · 1 repost

Conference abstracts

3808ONCT05740566matched by DeLLphi-304

DeLLphi-304 Read the abstract →

NCT05740566NCT05740566matched by - **标题 / Title：** Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

- **标题 / Title：** Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer Read the abstract →

Source: HHorinouchi · x.com